Mechanistic Pharmacology and Pharmacotherapy Unit, UCIBIO-i4HB, Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
Cells. 2023 Jun 22;12(13):1690. doi: 10.3390/cells12131690.
In the cerebral cortex, glutamate activates NMDA receptors (NMDARs), localized in noradrenergic neurons, inducing noradrenaline release that may have a permissive effect on glutamatergic transmission, and therefore, on the modulation of long-term plasticity. ATP is co-released with noradrenaline, and with its metabolites (ADP and adenosine) is involved in the purinergic modulation of electrically-evoked noradrenaline release. However, it is not known if noradrenaline release evoked by activation of NMDARs is also under purinergic modulation. The present study aimed to investigate and to characterize the purinergic modulation of noradrenaline release evoked by NMDARs. Stimulation of rat cortical slices with 30 µM NMDA increased noradrenaline release, which was inhibited by ATP upon metabolization into ADP and adenosine and by the selective agonists of A and A receptors, CPA and CGS2680, respectively. It was also inhibited by UTP and UDP, which are mainly released under pathophysiological situations. Characterization of the effects mediated by these compounds indicated the involvement of P2Y, P2Y, A and A receptors. It is concluded that, in the rat brain cortex, NMDA-evoked noradrenaline release is modulated by several purinergic receptors that may represent a relevant mechanism to regulate the permissive effect of noradrenaline on NMDA-induced neuroplasticity.
在大脑皮层中,谷氨酸激活 NMDA 受体(NMDARs),这些受体定位于去甲肾上腺素能神经元中,诱导去甲肾上腺素释放,这可能对谷氨酸能传递具有许可作用,从而对长时程可塑性进行调节。ATP 与去甲肾上腺素一起被共同释放,并且与它的代谢物(ADP 和腺苷)一起参与电刺激去甲肾上腺素释放的嘌呤能调制。然而,目前尚不清楚 NMDAR 激活引起的去甲肾上腺素释放是否也受到嘌呤能调制的影响。本研究旨在研究和表征 NMDAR 激活引起的去甲肾上腺素释放的嘌呤能调制。用 30µM NMDA 刺激大鼠皮质切片会增加去甲肾上腺素的释放,这种释放会被 ATP 代谢成 ADP 和腺苷、以及 A 受体和 A 受体的选择性激动剂 CPA 和 CGS2680 所抑制。它也被 UTP 和 UDP 抑制,这些物质主要在病理生理情况下释放。对这些化合物介导的作用进行特征描述表明涉及 P2Y、P2Y、A 和 A 受体。综上所述,在大鼠大脑皮层中,NMDAR 诱导的去甲肾上腺素释放受到几种嘌呤能受体的调制,这可能代表一种调节去甲肾上腺素对 NMDA 诱导的神经可塑性的许可作用的相关机制。